Discovered new test to measure progress of fatal neurodegenerative disease

0

This new blood test may be the answer on the way to preventing the risk of developing Huntington’s neurodegenerative disease, researchers have found, which they see as a giant breakthrough in treating a fatal condition.

The new blood test that may predict the risk of developing Huntington’s neurodegenerative disease was revealed this week by researchers in the field, who consider this a breakthrough in the treatment of this fatal problem.

In this study, already published in the scientific journal Lancet, is advanced with a new test that predicts when someone is at risk of contracting the disease and is still able to say how quickly the brain will degrade.

Huntington’s disease, which is transmitted genetically, has as its main symptoms involuntary movements, changes in personality and behavior, which end up making patients completely dependent until the end of their lives. Taking into account that it damages the muscles and also affects the vital systems, like the respiratory or the cardiac, thus ends, by causing death.

This international team of scientists has observed over the course of three years about 200 people with genes that indicate the likelihood of contracting Huntington’s disease, some volunteers already having manifestations, testing them regularly to measure the effects.

In blood samples, scientists looked for signs of the disease by measuring a protein released by the damaged brain cells and also finding that their presence in the blood increased with the progression of the problem in question.

Researcher Edward Wild, of University College London, also said that this protein “could serve as a ‘speedometer’ for Huntington’s disease”.

If this investigation proceeds and if it is concluded that it has no adverse effects, the test may become a cheaper and less invasive alternative for patients to measure the progress of the disease, which is currently Collection of cerebrospinal fluid and conducting tests on the brain.

Leave A Reply